Sexual transmission of the virus in human semen can occur 14, 15 but more evidence is required to confirm whether or not this is possible. ZIKV can be transmitted by blood transfusion. Cases of maternal fetal transmission have been confirmed. ZIKV can not be transmitted to babies through breast milk and the advice to mothers to breastfeed remains unchanged 16 .
Symptom
• Among the ZIKV infected person only 20-25% will manifest symptoms 17 . The clinical manifestations are generally similar to dengue and chikungunya infection with considerable overlap in symptoms, although ZIKV infections usually have milder clinical illness ,short lived , lasting only 2-7 days 18 .
· Incubation period 3-12 days 19 • Typical symptoms may include: a low grade fever, maculopapular rash, which may be itchy, nonpurulent conjunctivitis/red eyes, arthralgia (with possible swelling, mainly in the smaller joints of the hands and feet), myalgia, headache, and eye pain 20 .
• Serious complications from ZIKV are uncommon. However,an increase in cases of fetal microcephaly 22 , Guillain-Barresyndrome 23 and other neurological and autoimmune syndromes has been reported in areas where ZIKV outbreaks have occurred 24 .
How to diagnose ZIKV Indication of testing
Pregnant women with a history of travel to an area with Zika virus transmission and who report two or more symptoms consistent with Zika virus disease during or within 2 weeks of travel, or who have ultrasound findings of fetal microcephaly or intracranial calcifications, should be tested for Zika virus infection.
Testing is not indicated for women without a travel history to an area with Zika virus transmission.
• Reverse transcription polymerase chain reaction (RT-PCR) for for ZIKV in maternal serum of symptomatic patients.
• Antibody testing is less reliable due to potential cross-reaction with antibodies against other similar viruses (e.g. dengue or yellow fever 25 .
• Amniotic fluid study for ZIKV RT-PCR can also be performed although it is currently not known how sensitive or specific this test is for congenital infection, or the likelihood of an infected fetus being affected, i.e. subsequently developing a fetal abnormality 26, 27 . 25 . Pregnant women who are willing to travel to an area with Zika virus transmission, should strictly follow steps to avoid mosquito bites 25, 26 .
Treatment
The main vector for ZIKV, the Aedes mosquito is active predominantly during daylight hours. They commonly bite during mid-morning and late afternoon to dusk. On the other hand the Anopheles mosquito which transmits malaria is more active by night. Travellers should take all possible measures to minimise the chances of mosquito bites. This includes wearing lightcoloured, loose-fitting clothes that cover as much exposed skin as possible, for example long trousers and long sleeves specially during the daytime as much as possible. Clothing can be treated with an insecticide (e.g.permethrin) which kills insects, including mosquitoes.19N, N-diethyl meta toluamide (DEET) 50% based repellents are the most commonly available and are safe in pregnant and breastfeeding women (and in infants and children over the age of 2 months) 27, 28 . Insect repellents should not be ingested, and not come in contact with the eyes or mouth. Insect repellents should be re-applied regularly, particularly after swimming and in hot humid conditions when they may be removed by perspiration. When both sunscreen and insect repellents are required, the insect repellent should be applied over the sunscreen 29 .
Recommendations for Pregnant Women with History of Travel to an Area of Zika Virus Transmission
Women who traveled to an area with ongoing Zika virus transmission during pregnancy should be evaluated for Zika virus infection and tested in accordance with CDC Interim Guidance 30 . Because of the similar geographic distribution and clinical presentation of Zika, dengue, and chi-kungunya virus infection, patients with symptoms consistent with Zika virus disease should also be evaluated for dengue and chikungunya virus infection, in accordance with existing guidelines 31, 32 .Zika virus testing of maternal serum includes reverse transcription-polymerase chain reaction (RT-PCR) testing for symptomatic patients with onset of symptoms within the previous week. Immunoglobulin M (IgM) and neutralizing antibody testing should be performed on specimens collected e"4 days after onset of symptoms. Crossreaction with related flaviviruses (e.g., dengue or yellow fever) is common with anti-body testing, and thus it might be difficult to distinguish Zika virus infection from other flavi virus infections. Testing of asymptomatic pregnant women is not recommended in the absence of fetal microcephaly or intracranial calcifications. Zika virus RT-PCR testing can be performed on amniotic fluid (7, 9) . Currently, it is unknown how sensitive or specific this test is for congenital infection. Also, it is unknown if a positive result is predictive of a subsequent fetal abnormality, and if so, what proportion of infants born after infection will have abnormalities. Amniocentesis is associated with an overall 0.1% risk of pregnancy loss when performed at less than 24 weeks of gestation 33 . A positive RT-PCR result on amniotic fluid would be suggestive of intrauterine infection and potentially useful to pregnant women and their health care providers 34 .
Women reporting symptoms consistent with ZIKV disease
If a pregnant women have a history of travel to an area with active ZIKV transmission and present with symptoms consistent with ZIKV disease during or within two weeks of travel, should be tested for ZIKV infection and other travel associated infections(including malaria). If ZIKV is identified on laboratory testing, the woman should be referred to a fetal medicine service for further assessment. If the test for ZIKV is negative, serial (4-weekly) fetal ultrasound scans should be considered to monitor fetal growth and anatomy. Women whose symptoms have resolved by the time of presentation, ZIKV testing is not recommended but they too should be offered serial (4-weekly) fetal ultrasound scans. Routine testing of asymptomatic women (those who remained asymptomatic while travelling and for two weeks after their return from a ZIKV affected area) is not recommended. However, serial fetal ultrasound scans as above should be considered (as ZIKV infection is associated with minimal symptoms in the majority). Any woman in whom a small fetal head (Head Circumference more than 2 Standard Deviations below the mean for gestational age, i.e. below the 2.5 th centile) or brain abnormality(such as intracranial calcifications) is diagnosed on ultrasound, and who has previously visited a ZIKV affected area during pregnancy, should also be referred to a maternal fetal medicine service for further assessment. If diagnosis of fetal microcephaly or intracranial calcifications is made but women who have not travelled to a ZIKV affected area during pregnancy do not need to be tested. If fetal microcephaly or brain abnormality, such as intracranial calcification, is diagnosed, consideration should be given to performing an amniocentesis to test for the virus using RT-PCR. Amniocentesis is associated with a small risk of miscarriage or preterm birth and should not be performed before 15 weeks of gestation. Even if ZIKV positive, it is not known how sensitive or specific this test is for congenital infection, nor the likelihood of an infected fetus being affected. Nevertheless, if there is fetal abnormality on ultrasound and ZIKV PCR on amniocentesis is positive, then it is highly likely that the abnormality is ZIKV associated and that the outcome is likely to be poor. When brain abnormalities are identified on ultrasound scan, consideration should be given to performing fetal brain MRI which may detect abnormalities that have not been detected on ultrasound. When a significant brain abnormality or microcephaly is confirmed in the presence of ZIKV infection, the option of termination of pregnancy should be discussed with the woman, regardless of gestation.
Women planning pregnancy
While travelling in an area with active ZIKV transmission, women should be advised to avoid becoming pregnant. They should avoid becoming pregnant for a further 28 days on returning to home; this allows for a maximum two weeks incubation period and possible two-weeks viraemia. Women whose partner has been to an area with ZIKV transmission , the risk of sexual transmission of ZIKV is thought to be very low. However, ZIKV has been identified in Semen of men who have had ZIKV infection, and it is not known how long this can persist. If a woman's partner has travelled to a country with active ZIKV transmission, effective contraception is advised to avoid pregnancy (and the use of condoms could be considered to prevent against infection acquisition): for 28 days after his return home if he had no ZIKV symptoms, either whilst abroad or within 2 weeks of his leaving the affected country for 6 months following recovery if he did experience ZIKV symptoms during that period. 
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